No Data
No Data
Aclaris Therapeutics Assumed With an Overweight at Cantor Fitzgerald
Cantor Fitzgerald Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating
Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeuticsto Overweight
Scotiabank Initiates Coverage On Aclaris Therapeutics With Sector Outperform Rating, Announces Price Target of $15
Aclaris Therapeutics Analyst Ratings
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio